Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.
Hoog. Meredith M MM; Vallarino. Carlos C; Maldonado. Juan M JM; Grabner. Michael M; Teng. Chia-Chen CC; Terrell. Kendra K; Richard. Emma L EL
Key Findings
- Tirzepatide reduced HbA1c by about 1.3% in drug‑naïve patients versus 0.9% with semaglutide (and 0.9% vs 0.6% in those previously on GLP‑1 drugs).
- Weight loss was roughly 10.2 kg with tirzepatide versus 6.1 kg with semaglutide in naïve users (and 7.9 kg vs 3.7 kg in non‑naïve users).
- The superiority of tirzepatide was consistent across patients regardless of prior GLP‑1 receptor agonist exposure.
Practical Outcomes
- For biohackers and self‑experimenters aiming for better glucose control and significant fat loss, tirzepatide appears to be a more potent option than semaglutide. Starting tirzepatide at the recommended low dose and titrating upward, while monitoring blood sugar and weight, can maximize benefits. Expect stronger results even if you’ve already tried other GLP‑1 drugs.
Summary
In everyday patients with type‑2 diabetes, the drug tirzepatide lowered blood sugar and trimmed body weight more than the already‑popular drug semaglutide, and it did so whether or not people had used similar medicines before.
Abstract
To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management. This retrospective analysis utilized the Healthcare Integrated Research Database® to identify adults with T2D starting tirzepatide or injectable semaglutide between May 13, 2022 and May 29, 2023. GLP-1 RA naïve and non-naïve cohorts were identified based on the history of GLP-1 RA use within ≤ 6 months of initiation. Propensity score matching balanced 6-month baseline characteristics between groups. HbA1c and weight changes were assessed from initiation to 12 months for matched patients with HbA1c and weight data at both time points. Both matched naïve cohorts were comprised of 10,702 patients (tirzepatide: 1399 with HbA1c data and 454 with weight data; semaglutide: 1173 with HbA1c data and 432 with weight data). Mean baseline HbA1c and weight were 7.8% and 112.4 kg, respectively, for the tirzepatide group and 7.8% and 110.7 kg for the semaglutide group. Both matched non-naïve cohorts were comprised of 5577 patients (tirzepatide: 792 with HbA1c data and 296 with weight data; semaglutide: 738 with HbA1c data and 224 with weight data). Mean baseline HbA1c and weight were 7.7% and 112.5 kg for tirzepatide, and 7.9% and 108.5 kg for semaglutide. Tirzepatide was associated with greater mean reductions in HbA1c (naïve: - 1.3% vs. - 0.9%; non-naïve: - 0.9% vs. - 0.6%; p < 0.001) and weight (naïve: - 10.2 kg vs. - 6.1 kg; non-naïve: - 7.9 kg vs. - 3.7 kg; p < 0.001) than semaglutide. Patients with T2D starting tirzepatide had greater HbA1c and weight reductions at 12 months post-initiation than those on injectable semaglutide, regardless of previous GLP-1 RA use, consistent with previous clinical trial results.
Study Information
pubmed
2025
2025-10-09T00:00:00.000Z
10.1007/s13300-025-01794-9
39